NSCLC Biomarkers Quiz #4

MET exon 14 skipping mutations occur in approximately how many patients with NSCLC?
3-4%
1-6%
3-10%
1-3%
Which of the following therapies has been previously used off-label to treat patients with MET exon 14 skipping mutations?
Capmatinib
Cabozantinib
Tepotinib
Crizotinib
RET fusions are more common in elderly patients who are smokers.
True
False
Which of the following are FDA-approved for adult patients with advanced NSCLC with a RET fusion-positive NSCLC.
Capmatinib
Cabozantinib
Pralsetinib
Tepotinib
0
{"name":"NSCLC Biomarkers Quiz #4", "url":"https://www.poll-maker.com/QC53SA7JQ","txt":"MET exon 14 skipping mutations occur in approximately how many patients with NSCLC?, Which of the following therapies has been previously used off-label to treat patients with MET exon 14 skipping mutations?, RET fusions are more common in elderly patients who are smokers.","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys